Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failure. We aimed to investigate the clinical outcomes of patients with advanced HCC who received subsequent systemic therapy for disease progression after ATE+BEV. Methods: This multicenter, retrospective study included patients who started second-line systemic treatment with sorafenib or lenvatinib after HCC progressed on ATE+BEV between August 2019 and December 2022. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.). Clinical features of the two groups were balanced through propensity score (PS) matching. Results: This study enrolled 126 patients, 40 (31.7%) in the lenvatinib group, and 86 (68.3%) in the sorafenib group. The median age was 63 years, and males were predominant (88.1%). In PS-matched cohorts (36 patients in each group), the objective response rate was similar between the lenvatinib- and sorafenib-treated groups (5.6% vs. 8.3%; P=0.643), but the disease control rate was superior in the lenvatinib group (66.7% vs. 22.2%; P<0.001). Despite the superior progression-free survival (PFS) in the lenvatinib group (3.5 vs. 1.8 months, P=0.001), the overall survival (OS, 10.3 vs. 7.5 months, P=0.353) did not differ between the two PS-matched treatment groups. Conclusions: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer followups are needed to optimize second-line treatment.
Abstract
Background/Aims: Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failure. We aimed to investigate the clinical outcomes of patients with advanced HCC who received subsequent systemic therapy for disease progression after ATE+BEV. Methods: This multicenter, retrospective study included patients who started second-line systemic treatment with sorafenib or lenvatinib after HCC progressed on ATE+BEV between August 2019 and December 2022. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.). Clinical features of the two groups were balanced through propensity score (PS) matching. Results: This study enrolled 126 patients, 40 (31.7%) in the lenvatinib group, and 86 (68.3%) in the sorafenib group. The median age was 63 years, and males were predominant (88.1%). In PS-matched cohorts (36 patients in each group), the objective response rate was similar between the lenvatinib- and sorafenib-treated groups (5.6% vs. 8.3%; P=0.643), but the disease control rate was superior in the lenvatinib group (66.7% vs. 22.2%; P<0.001). Despite the superior progression-free survival (PFS) in the lenvatinib group (3.5 vs. 1.8 months, P=0.001), the overall survival (OS, 10.3 vs. 7.5 months, P=0.353) did not differ between the two PS-matched treatment groups. Conclusions: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer followups are needed to optimize second-line treatment.
참고문헌 (25)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- Kim BH, "Epidemiology of liver cancer in South Korea", Clin Mol Hepatol, 24, pp.1~9 (2018)
- Bruix J, "Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma", Gastroenterology, 150, pp.835~853 (2016)
- Bertuccio P, "Global trends and predictions in hepatocellular carcinoma mortality", J Hepatol, 67, pp.302~309 (2017)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
- Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
- Benson AB, "Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 19, pp.541~565 (2021)
- Su GL, "et al AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma", Gastroenterology, 162, pp.920~934 (2022)
- Llovet JM, "Molecular pathogenesis and systemic therapies for hepatocellular carcinoma", Nat Cancer, 3, pp.386~401 (2022)
- Chen CT, "Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment", Hepatol Int, 16, pp.1199~1207 (2022)
- Yoo C, "Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : A multinational multicenter retrospective study", Liver Cancer, 10, pp.107~114 (2021)
- Chen YH, "Efficacy and safety of lenvatinib after progression on first-line atezolizumab plus bevacizumab treatment in advanced hepatocellular carcinoma patients", Anticancer Res, 43, pp.1377~1384 (2023)
- Falette-Puisieux M, "Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting", Ther Adv Med Oncol, 15, pp.17588359231189425~ (2023)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Schwartz LH, "RECIST 1. 1-Standardisation and diseasespecific adaptations : Perspectives from the RECIST Working Group", Eur J Cancer, 62, pp.138~145 (2016)
- Persano M, "Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients", Eur J Cancer, 189, pp.112933~ (2023)
- Kim BK, "Atezolizumab", bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma : A real-world, multicenter study, 2022, pp.14, 1747~
- Hiraoka A, "Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma : Clinical results show importance of hepatic reserve function", Oncology, 101, pp.624~633 (2023)
- Yano S, "Therapeutic efficacy and safety of lenvatinib after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma", Cancers(Basel), 15, pp.5406~ (2023)
- Palmer ME, "Outcomes of patients with advanced hepatocellular carcinoma receiving lenvatinib following immunotherapy : A real world evidence study", Cancers(Basel), 15, pp.4867~ (2023)
- Cheon J, "Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab : REGONEXT trial", J Clin Oncol, 41(4Suppl), pp.TPS634~TPS634 (2023)
- Chan SL, "A phase II clinical trial to study the use of cabozantinib(cabo)in patients with hepatocellular carcinoma(HCC)post immunotherapy treatment", J Clin Oncol, 41(4 Suppl), pp.571~571 (2023)
- Frenette C, "How to choose second-line treatment for hepatocellular carcinoma", Clin Adv Hematol Oncol, 19, pp.726~729 (2021)